Todd Asset Management LLC Buys New Holdings in Smith & Nephew SNATS, Inc. $SNN

Todd Asset Management LLC purchased a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 725,230 shares of the medical equipment provider’s stock, valued at approximately $26,319,000.

Other large investors also recently modified their holdings of the company. Bank of Montreal Can lifted its stake in shares of Smith & Nephew SNATS by 321.6% in the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after purchasing an additional 2,616,301 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Smith & Nephew SNATS by 6,663.4% in the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock valued at $37,082,000 after buying an additional 1,192,755 shares during the period. ABC Arbitrage SA lifted its position in Smith & Nephew SNATS by 1,063.4% during the second quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after buying an additional 821,393 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after buying an additional 583,809 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Smith & Nephew SNATS by 365.1% during the second quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock worth $19,742,000 after buying an additional 505,934 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Canaccord Genuity Group reduced their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Smith & Nephew SNATS has a consensus rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $36.16 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The business has a 50 day moving average price of $33.48 and a two-hundred day moving average price of $34.82.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.